Advertisement

Topics

Sandoz gets EC nod for Rixathon to treat blood cancers and immunological diseases

02:47 EDT 20 Jun 2017 | Pharmaceutical Business Review

Novartis subsidiary Sandoz has secured approval from the European Commission (EC) for its Rixathon (biosimilar rituximab) to treat blood cancers and immunological diseases.

Original Article: Sandoz gets EC nod for Rixathon to treat blood cancers and immunological diseases

NEXT ARTICLE

More From BioPortfolio on "Sandoz gets EC nod for Rixathon to treat blood cancers and immunological diseases"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...

Biosimilars
Biosimilars or Follow-on biologics are terms used to describe officially approved subsequent versions of innovator biopharmaceutical products made by a different sponsor following patent and exclusivity expiry on the innovator product. Products that ar...

Monoclonal antibodies MAbs
Monoclonal antibodies recognise and attach to specific proteins produced by cells.  Types of monoclonal antibodies used to treat cancer cells: Block cell dividing dividing signals Transport cancer drugs or radiation to cancer cells Tr...